miR‑142‑5p inhibits pancreatic cancer cell migration and invasion by targeting PIK3CA

Zhu,Jing; Zhou,Leilei; Wei,Bin; Qian,Zhaoye; Wang,Jiru; Hui,Hongxia; Sun,Yuan

doi:10.3892/mmr.2020.11251

miR‑142‑5p inhibits pancreatic cancer cell migration and invasion by targeting PIK3CA

Authors:
- Jing Zhu
- Leilei Zhou
- Bin Wei
- Zhaoye Qian
- Jiru Wang
- Hongxia Hui
- Yuan Sun
View Affiliations

Affiliations: Department of Medical Oncology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China
Published online on: June 18, 2020 https://doi.org/10.3892/mmr.2020.11251
Pages: 2085-2092

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer is a fatal disease with a high mortality rate and poor prognosis worldwide. The aberrant expression of microRNAs (miRs) is associated with cancer development and progression. The present study aimed to evaluate the functional role of miR‑142‑5p in migration and invasion, and investigated its underlying molecular mechanism in pancreatic cancer cells. First, it was identified that miR‑142‑5p expression was downregulated in pancreatic cancer tissues and cell lines by reverse transcription‑quantitative polymerase chain reaction. Furthermore, phosphoinositide‑3‑kinase catalytic subunit α (PIK3CA) was identified as a target of miR‑142‑5p. The expression of PIK3CA was upregulated in tumor tissues and its expression was negatively regulated by miR‑142‑5p expression. Notably, overexpression of miR‑142‑5p inhibited the proliferation, migration and invasion of PanC1 cells, while PIK3CA reversed this inhibition. In addition, miR‑142‑5p suppressed the expression of focal adhesion kinase (FAK) and matrix metalloproteinase (MMP)9, as well as phosphorylated protein kinase B (AKT) protein level, while PIK3CA reversed the suppression induced by miR‑142‑5p. In conclusion, miR‑142‑5p functions as a tumor suppressor, which inhibits the migration and invasion of pancreatic cancer by suppressing the expression of FAK and MMP9, as well as the phosphatidylinositol 3‑kinase/AKT signaling pathway by targeting PIK3CA. These findings suggest that miR‑142‑5p may be a novel therapeutic target for the treatment of pancreatic cancer.

View Figures

View References

1	Kamisawa T, Wood LD, Itoi T and Takaori K: Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
2	Lin QJ, Yang F, Jin C and Fu DL: Current status and progress of pancreatic cancer in China. World J Gastroenterol. 21:7988–8003. 2015. View Article : Google Scholar : PubMed/NCBI
3	Goral V: Pancreatic cancer: Pathogenesis and diagnosis. Asian Pac J Cancer Prev. 16:5619–5624. 2015. View Article : Google Scholar : PubMed/NCBI
4	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
5	Carrato A, Falcone A, Ducreux M, Valle JW, Parnaby A, Djazouli K, Alnwick-Allu K, Hutchings A, Palaska C and Parthenaki I: A systematic review of the burden of pancreatic cancer in Europe: Real-world impact on survival, quality of life and costs. J Gastrointest Cancer. 46:201–211. 2015. View Article : Google Scholar : PubMed/NCBI
6	Su D, Yamaguchi K and Tanaka M: The characteristics of disseminated tumor cells in pancreatic cancer: A black box needs to be explored. Pancreatology. 5:316–324. 2005. View Article : Google Scholar : PubMed/NCBI
7	Li X, Li Y, Wan L, Chen R and Chen F: miR-509-5p inhibits cellular proliferation and migration via targeting MDM2 in pancreatic cancer cells. Onco Targets Ther. 10:4455–4464. 2017. View Article : Google Scholar : PubMed/NCBI
8	Stathis A and Moore MJ: Advanced pancreatic carcinoma: Current treatment and future challenges. Nat Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
9	Ambros V: microRNAs: Tiny regulators with great potential. Cell. 107:823–826. 2001. View Article : Google Scholar : PubMed/NCBI
10	Hammond SM: An overview of microRNAs. Adv Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
11	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
12	Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G and Calin GA: microRNA therapeutics in cancer-an emerging concept. EBioMedicine. 12:34–42. 2016. View Article : Google Scholar : PubMed/NCBI
13	Hata A and Lieberman J: Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal. 8:re32015. View Article : Google Scholar : PubMed/NCBI
14	Simonson B and Das S: MicroRNA therapeutics: The next magic bullet? Mini Rev Med Chem. 15:467–474. 2015. View Article : Google Scholar : PubMed/NCBI
15	Shrestha A, Mukhametshina RT, Taghizadeh S, Vasquez-Pacheco E, Cabrera-Fuentes H, Rizvanov A, Mari B, Carraro G and Bellusci S: MicroRNA-142 is a multifaceted regulator in organogenesis, homeostasis, and disease. Dev Dynam. 246:285–290. 2017. View Article : Google Scholar
16	Jia L, Xi Q, Wang H, Zhang Z, Liu H, Cheng Y, Guo X, Zhang J, Zhang Q, Zhang L, et al: miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. Biochem Biophys Res Commun. 488:425–431. 2017. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Liu L, Liu S, Duan Q, Chen L, Wu T, Qian H, Yang S, Xin D, He Z and Guo Y: MicroRNA-142-5p promotes cell growth and migration in renal cell carcinoma by targeting BTG3. Am J Transl Res. 9:2394–2402. 2017.PubMed/NCBI
19	Islam F, Gopalan V, Vider J, Lu CT and Lam AK: MiR-142-5p act as an oncogenic microRNA in colorectal cancer: Clinicopathological and functional insights. Exp Mol Pathol. 104:98–107. 2018. View Article : Google Scholar : PubMed/NCBI
20	Liu S, Xiao Z, Ai F, Liu F, Chen X, Cao K, Ren W, Zhang X, Shu P and Zhang D: miR-142-5p promotes development of colorectal cancer through targeting SDHB and facilitating generation of aerobic glycolysis. Biomed Pharmacother. 92:1119–1127. 2017. View Article : Google Scholar : PubMed/NCBI
21	Wang Z, Liu Z, Fang X and Yang H: MiR-142-5p suppresses tumorigenesis by targeting PIK3CA in non-small cell lung cancer. Cell Physiol Biochem. 43:2505–2515. 2017. View Article : Google Scholar : PubMed/NCBI
22	Tsang FH, Au SL, Wei L, Fan DN, Lee JM, Wong CC, Ng IO and Wong CM: MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility. Front Med. 9:331–343. 2015. View Article : Google Scholar : PubMed/NCBI
23	Lou K, Chen N, Li Z, Zhang B, Wang X, Chen Y, Xu H, Wang D and Wang H: MicroRNA-142-5p overexpression inhibits cell growth and induces apoptosis by regulating FOXO in hepatocellular carcinoma cells. Oncol Res. 25:65–73. 2017. View Article : Google Scholar : PubMed/NCBI
24	Samuels Y and Waldman T: Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol. 347:21–41. 2010.PubMed/NCBI
25	Vanhaesebroeck B, Stein RC and Waterfield MD: The study of phosphoinositide 3-kinase function. Cancer Surv. 27:249–270. 1996.PubMed/NCBI
26	Zhang S, Cai J, Xie W, Luo H and Yang F: miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA. Exp Ther Med. 16:1499–1504. 2018.PubMed/NCBI
27	Meng F and Zhang L: miR-183-5p functions as a tumor suppressor in lung cancer through PIK3CA inhibition. Exp Cell Res. 374:315–322. 2019. View Article : Google Scholar : PubMed/NCBI
28	Yu QQ, Wu H, Huang X, Shen H, Shu YQ, Zhang B, Xiang CC, Yu SM, Guo RH and Chen L: MiR-1 targets PIK3CA and inhibits tumorigenic properties of A549 cells. Biomed Pharmacother. 68:155–161. 2014. View Article : Google Scholar : PubMed/NCBI
29	Liang M, Shi B, Liu J, He L, Yi G, Zhou L, Yu G and Zhou X: Downregulation of miR203 induces overexpression of PIK3CA and predicts poor prognosis of gastric cancer patients. Drug Des Devel Ther. 9:3607–3616. 2015.PubMed/NCBI
30	Chen K, Zeng J, Tang K, Xiao H, Hu J, Huang C, Yao W, Yu G, Xiao W, Guan W, et al: miR-490-5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA. Biol Cell. 108:41–50. 2016. View Article : Google Scholar : PubMed/NCBI
31	Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al: Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 518:495–501. 2015. View Article : Google Scholar : PubMed/NCBI
32	Lv PC, Jiang AQ, Zhang WM and Zhu HL: FAK inhibitors in Cancer, a patent review. Expert Opin Ther Pat. 28:139–145. 2018. View Article : Google Scholar : PubMed/NCBI
33	Knapinska AM, Estrada CA and Fields GB: The roles of matrix metalloproteinases in pancreatic cancer. Prog Mol Biol Transl Sci. 148:339–354. 2017. View Article : Google Scholar : PubMed/NCBI
34	Xu X, Gao F, Wang J, Tao L, Ye J, Ding L, Ji W and Chen X: MiR-122-5p inhibits cell migration and invasion in gastric cancer by down-regulating DUSP4. Cancer Biol Ther. 19:427–435. 2018. View Article : Google Scholar : PubMed/NCBI
35	Zou Q, Yi W, Huang J, Fu F, Chen G and Zhong D: MicroRNA-375 targets PAX6 and inhibits the viability, migration and invasion of human breast cancer MCF-7 cells. Exp Ther Med. 14:1198–1204. 2017. View Article : Google Scholar : PubMed/NCBI
36	Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis. 9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
37	Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
38	Weber GL, Parat MO, Binder ZA, Gallia GL and Riggins GJ: Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget. 2:833–849. 2011. View Article : Google Scholar : PubMed/NCBI